報價延遲最少15分鐘:2026/05/19 10:09 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
-- 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.15/--
|
|
企業價值
1.24B
|
| 資產負債 |
|
每股賬面淨值
0.69
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
8.65M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improvepatient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR). |
